NEJM: Sogle net effective treatment for diabetics with chronic kidney disease

Evidence of support for the use of sodium/glucose co-transporter 2 (SGLT2) inhibitors has increased since a new treatment for type 2 diabetes was approved by the U.S. Food and Drug Administration (FDA).
have shown that diabetics who take SGLT2 inhibitors have better blood sugar control, cardiovascular benefits, and weight loss.
Now, two large clinical trials, called SCORED and SOLOIST, sponsored by researchers at The Bregan Women's Hospital in the United States, have added new evidence of benefits for people with chronic kidney disease and those with diabetes with recent worsening heart failure.
the two paired clinical trials, a team led by Dr. Deepak L. Bhatt, a cardiologist at Bregan Women's Hospital, evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1.
results of both clinical trials were published online November 16, 2020 in the journal NEJM under the titles "Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease" and "Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure."
The results of these two large clinical trials, together with other recent data on these drugs, now make it clear that most patients with type 2 diabetes with kidney disease or heart failure should use SGLT2 inhibitors," said Bhatt, a synthetic route for sotagliflozin.
further randomized clinical trial evidence from SCORED suggests that SGLT2 inhibitors should be part of standard care for patients with type 2 diabetes with kidney disease.
and SOLOIST showed that early in-hospital treatment of SGLT2 inhibitors was safe and effective and should be standard care for patients with type 2 diabetes with heart failure.
" Sogle Net was developed and transferred to Lescon Pharmaceuticals by Sanofi, which not only inhibits SGLT2, but also SGLT1.
SGLT2 inhibition helps the body remove blood sugar through urine, while SGLT1 inhibition lowers blood sugar through the digestive tract.
in a CLINICAL clinical trial, the Bhatt team assessed whether Soglein could prevent cardiovascular events in patients with chronic kidney disease.
conducted a multi-center, double-blind clinical trial that included 10,584 patients, with an average follow-up of 16 months.
clinical trial ended early due to a loss of COVID-related sponsorship funding.
in the case of data blindness, they changed the main endpoint;
unlike previous clinical trials, SCORED recruited patients with varying degrees of proteinuria, which refers to protein infiltration into urine, which can occur when a person has diabetes.
the primary endpoint of cardiovascular death, hospitalization for heart failure, or emergency care for heart failure was significantly reduced by about 26 percent, regardless of the patient's level of proteinuria.
, Sogler net also reduces the incidence of cardiovascular death, myocardial infarction, or stroke, and early benefits may be mediated by SGLT1 inhibition.
, the total number of fatal or non-fatal heart attacks and the total number of fatal or non-fatal strokes decreased by 32% and 34%, respectively.
SGLT2 inhibitors are the first clinical trials to show the benefits of SGLT2 inhibitors in patients with varying degrees of proteinuria," said Bhatt.
is also the first clinical trial in which SGLT2 inhibitors have shown benefits for stroke.
" SOLOIST clinical trial recruited 1,222 people with type 2 diabetes who needed hospitalization for recent worsening heart failure.
patients were randomly treated with sogrides or placebos for an average of 9 months.
clinical trials ended early because of the loss of sponsorship funding during the COVID-19 pandemic.
patient data from patients who participated in the clinical trial showed that the main endpoints of the study ---cully the overall incidence of cardiovascular death, hospitalization for heart failure, and emergency visits to heart failure--- significantly reduced the risk of heart failure by 33 percent for patients with reduced or retained blood test scores.
is safe and effective to take the drug before discharge.
SORIST is the first large randomized clinical trial to demonstrate the safety and effectiveness of SGLT2 inhibitors when activated in hospitalized patients with acute heart failure," said Dr. Bhatt.
, it really changed the field and supported the early start-up of these drugs.
" Reference: 1. Deepak L. Bhatt et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2020, doi:10.1056/NEJMoa2030186.2.Deepak L. Bhatt et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2020, doi:10.1056/NEJMoa2030183.3.SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 resedors This article was originally published from Bio Valley, for more information please download Bio Valley APP (